Cargando…

Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy

INTRODUCTION: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinson, Lewis, Corey, Alfred, Hanfling, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766/
https://www.ncbi.nlm.nih.gov/pubmed/28856066
http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d
_version_ 1783256968283029504
author Rubinson, Lewis
Corey, Alfred
Hanfling, Dan
author_facet Rubinson, Lewis
Corey, Alfred
Hanfling, Dan
author_sort Rubinson, Lewis
collection PubMed
description INTRODUCTION: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an anti-PA monoclonal antibody, has been approved for therapeutic use using the Animal Rule. Given the paucity of human inhalational anthrax clinical data including PA kinetics, the post-exposure period for effective treatment of human disease remains unknown. The objective of this investigation was to extrapolate animal PA kinetics to a conceptual human model to estimate the post-exposure period for effective treatment of human inhalational anthrax. METHODS: Human PA kinetic parameters were extrapolated from reported rabbit and monkey data. PA profiles were simulated with and without antibiotic induced PA clearance to represent antibiotic-sensitive and -resistant infections, respectively. Antitoxin levels equimolar to or greater than concurrent PA levels were considered protective. RESULTS: For antibiotic sensitive infections, treatment with antibiotics alone ≤4 days after spore exposure prevents toxemia. Administration of raxibacumab together with antibiotics protects ≥ 80% of subjects for 3 additional days (7 days post exposure). In the setting of antibiotic resistance, raxibacumab would be protective for at least 6 days post exposure. CONCLUSIONS: Although the animal model of disease does not reflect the potential impact of supportive care (e.g. fluid resuscitation received by critically ill patients) on PA kinetics and raxibacumab PK, the simulations suggest that administration of antitoxin in combination with antibiotics should provide a longer postexposure window for effective treatment than for antibiotics alone. In addition, raxibacumab administration soon after exposure to an antibiotic resistant strain should provide effective treatment.
format Online
Article
Text
id pubmed-5555766
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55557662017-08-29 Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy Rubinson, Lewis Corey, Alfred Hanfling, Dan PLoS Curr Research Article INTRODUCTION: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an anti-PA monoclonal antibody, has been approved for therapeutic use using the Animal Rule. Given the paucity of human inhalational anthrax clinical data including PA kinetics, the post-exposure period for effective treatment of human disease remains unknown. The objective of this investigation was to extrapolate animal PA kinetics to a conceptual human model to estimate the post-exposure period for effective treatment of human inhalational anthrax. METHODS: Human PA kinetic parameters were extrapolated from reported rabbit and monkey data. PA profiles were simulated with and without antibiotic induced PA clearance to represent antibiotic-sensitive and -resistant infections, respectively. Antitoxin levels equimolar to or greater than concurrent PA levels were considered protective. RESULTS: For antibiotic sensitive infections, treatment with antibiotics alone ≤4 days after spore exposure prevents toxemia. Administration of raxibacumab together with antibiotics protects ≥ 80% of subjects for 3 additional days (7 days post exposure). In the setting of antibiotic resistance, raxibacumab would be protective for at least 6 days post exposure. CONCLUSIONS: Although the animal model of disease does not reflect the potential impact of supportive care (e.g. fluid resuscitation received by critically ill patients) on PA kinetics and raxibacumab PK, the simulations suggest that administration of antitoxin in combination with antibiotics should provide a longer postexposure window for effective treatment than for antibiotics alone. In addition, raxibacumab administration soon after exposure to an antibiotic resistant strain should provide effective treatment. Public Library of Science 2017-07-28 /pmc/articles/PMC5555766/ /pubmed/28856066 http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d Text en © 2017 Rubinson, Corey, Hanfling, et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rubinson, Lewis
Corey, Alfred
Hanfling, Dan
Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title_full Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title_fullStr Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title_full_unstemmed Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title_short Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy
title_sort estimation of time period for effective human inhalational anthrax treatment including antitoxin therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766/
https://www.ncbi.nlm.nih.gov/pubmed/28856066
http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d
work_keys_str_mv AT rubinsonlewis estimationoftimeperiodforeffectivehumaninhalationalanthraxtreatmentincludingantitoxintherapy
AT coreyalfred estimationoftimeperiodforeffectivehumaninhalationalanthraxtreatmentincludingantitoxintherapy
AT hanflingdan estimationoftimeperiodforeffectivehumaninhalationalanthraxtreatmentincludingantitoxintherapy